US2023115839A1PendingUtilityA1
Methods For Treating Hypersomnia
Est. expiryApr 15, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Lyndon Lien
A61K 9/0053C07D 487/04A61K 9/20A61K 31/55A61P 25/00A61K 9/48
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are methods, formulations, and dosing regimens for treating hypersomnia in a subject. For instance, methods provided herein comprise administering a GABAA chloride channel blocker. In certain embodiments, the GABAA chloride channel blocker is pentylenetetrazol (PTZ).
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A pharmaceutical composition useful for treating idiopathic hypersomnia in a subject comprising pentylenetetrazol (PTZ) and a pharmaceutically acceptable excipient.
2 . The pharmaceutical composition of claim 1 in the form or a capsule or tablet.
3 . The pharmaceutical composition of claim 2 wherein the tablet is enteric-coated.
4 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is lactose, sucrose, mannitol, starch, or cellulose.
5 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is magnesium stearate, stearic acid, sodium saccharin, talcum, or magnesium carbonate.
6 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is iron oxide, silica gel, sodium lauryl sulfate, or titanium dioxide.
7 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is a pH buffering agent.
8 . The pharmaceutical composition of claim 7 wherein the pH buffering agent is a phosphate salt providing a phosphate buffered solution.
9 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is a diluent selected from physiological saline, phosphate buffered saline, and dextrose solution.
10 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is polyethylene glycol.
11 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is poly lactic-glycolic acid (PLGA), poly-(I)-lactic-glycolic-tartaric acid (P(I)LGT), polylactic acid, poly(ε-caprolactone), or poly(alkylene oxide).
12 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is triacetin.
13 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is gelatin.
14 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is a carrier selected from glucose.
15 . The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable excipient is a carrier selected from an amino acid.
16 . The pharmaceutical composition of claim 1 wherein the PTZ is at a dose of about 1 mg to 1,500 mg.
17 . The pharmaceutical composition of claim 1 wherein the PTZ is at a dose of about 5 mg to 1,000 mg.
18 . The pharmaceutical composition of claim 1 wherein the PTZ is at a dose of about mg to 800 mg.
19 . The pharmaceutical composition of claim 1 wherein the PTZ is at a dose of about 25 mg to 600 mg.Join the waitlist — get patent alerts
Track US2023115839A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.